BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) posted its earnings results on Monday. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14), Zacks reports.
BriaCell Therapeutics Stock Up 6.2 %
BriaCell Therapeutics stock opened at $0.65 on Wednesday. The stock has a 50-day moving average price of $0.82 and a 200 day moving average price of $0.86. The company has a market capitalization of $23.36 million, a price-to-earnings ratio of -0.55 and a beta of 1.46. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $5.97.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of BriaCell Therapeutics in a research note on Thursday, December 12th.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Trump’s China Tariffs Could Reshape These 2 Semiconductor Stocks
- Airline Stocks – Top Airline Stocks to Buy Now
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- Investing in Travel Stocks Benefits
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
